Inactive Instrument

HedgePath Pharmaceuticals Inc Stock

US42278K1025

Biotechnology & Medical Research

Press Releases: HedgePath Pharmaceuticals Inc

20/08/19	HedgePath Pharmaceuticals : Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019	PR
07/03/19	HedgePath Pharmaceuticals : Provides Corporate Update for the Fourth Quarter and Year End 2018	PR
09/07/18	HedgePath Pharmaceuticals : Closes Second Tranche of Mayne Pharma Financing	PR
14/05/18	HedgePath Pharmaceuticals : Announces Expanded Patent Coverage	PR
11/01/18	HedgePath Pharmaceuticals : Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs	PR

More press releases

Managers and Directors: HedgePath Pharmaceuticals Inc

Manager	Title	Age	Since
Frank O'Donnell CEO	Chief Executive Officer	76	13/12/2022
James McNulty DFI	Director of Finance/CFO	75	13/12/2022
Simon Bettink COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Frank O'Donnell CHM	Chairman	76	13/12/2022
Samuel Sears BRD	Director/Board Member	82	02/08/2013
Ronald Osman BRD	Director/Board Member	80	23/08/2023

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEDGEPATH PHARMACEUTICALS INC	-27.42%	-3.08%	-	-	32.23M
LONZA GROUP AG	+0.14%	-0.67%	-0.88%	+11.02%	47.74B
REVOLUTION MEDICINES, INC.	-3.12%	-0.73%	+388.33%	+607.70%	39.98B
BEONE MEDICINES AG	+0.77%	+2.95%	+11.40%	+45.73%	36.23B
IQVIA HOLDINGS INC.	+11.47%	+17.65%	+19.94%	+4.89%	35.59B
CELLTRION, INC.	-0.73%	+2.78%	+4.65%	+41.16%	27.91B
ASCENDIS PHARMA A/S	-1.06%	-1.92%	-	-	16.71B
MEDPACE HOLDINGS, INC.	-2.50%	+8.19%	+26.97%	+125.74%	16.45B
EUROFINS SCIENTIFIC SE	+2.39%	-1.64%	+4.74%	+9.95%	13.21B
ICON PUBLIC LIMITED COMPANY	+6.52%	+8.04%	-5.09%	-28.61%	12.93B
Average	-1.32%	+2.78%	+56.26%	+102.20%	27.42B
Weighted average by Cap.	+1.52%	+2.95%	+74.67%	+128.81%

See all sector performances

HedgePath Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for patients with certain cancers. The Company may also explore acquiring or licensing other therapeutics addressing unmet needs and orphan indications beyond cancer. The Company's preliminary focus is on the development of therapies for skin, lung and prostate cancers in the United States, with an indication targeting basal cell carcinoma (BCC) in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS, also known as Gorlin Syndrome). As of December 31, 2016, the Company was engaged in conducting an open label, Phase IIb clinical trial of a therapy for BCCNS. The Company's therapy is based upon super bioavailability (SUBA)-Itraconazole, an oral formulation of the marketed anti-fungal drug, itraconazole.

Employees

Sector

Biotechnology & Medical Research

More about the company